tiprankstipranks
Trending News
More News >
Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496)
:2496
Hong Kong Market
Advertisement

Wuhan YZY Biopharma Co., Ltd. Class H (2496) Revenue

Compare
1 Followers

Wuhan YZY Biopharma Co., Ltd. Class H Revenue

Wuhan YZY Biopharma Co., Ltd. Class H had a revenue of 22.18M in the quarter ending Jun 30, 2025, with 0.00%. This bring the company's revenue in the last twelve months to 149.35M, Decreased 16.15%. In the fiscal year ending Dec 31, 2024, Wuhan YZY Biopharma Co., Ltd. Class H had annual revenue of 107.81M with 804.31% growth.
Revenue (ttm)
149.35M
Revenue Growth
P/S Ratio
Revenue/Employee
HK$954,097
Employees
113
Market Cap

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
107.81M95.89M+904.31%
Dec 31, 2023
11.92M9.66M+526.87%
Dec 31, 2022
2.26M-9.91M+18.58%
Dec 31, 2021
12.18M
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis